Skip to main content

Advertisement

Table 2 Association between clinical markers and Menacalc expression (n = 403)

From: Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Characteristic Menacalc low Menacalc high P-valuec
   (n = 202) (n = 201)
   Number % Number %  
Death       
  Yes 22 10.9 36 17.9 0.0447
  No 180 89.1 165 82.1  
Menopausal status      
  pre 72 35.6 79 39.3 0.6969
  peri 9 4.5 10 5.0  
  post 121 59.9 112 55.7  
Tumor Size      
  <0.5 cm 2 1.0 3 1.5 0.8845
  0.5 to < 1.0 cm 21 10.4 20 10.0  
  1.0 to < 2.0 cm 91 45.0 83 41.2  
  2 to 5 cm 80 39.6 84 41.8  
  >5 cm 8 4.0 11 5.5  
Estrogen receptor      
  Positive 124 61.4 115 57.2 0.3701
  Negative/Equivocal 46 22.8 58 28.9 0.1926d
  NDa 32 15.8 28 13.9  
Progesterone receptor      
  Positive 112 55.5 103 51.3 0.4136
  Negative/Equivocal 58 28.7 70 34.8 0.2245d
  NDa 32 15.8 28 13.9  
Histological grade      
  1b 58 28.7 41 20.4 0.2389
  2 71 35.2 76 37.8  
  3 60 29.7 72 35.8  
  NDa 13 6.4 12 6.0  
Adjuvant treatment      
  Hormonal 76 37.6 93 46.3 0.0985
  Chemotherapy 37 18.3 41 20.4  
  Both 10 5.0 4 2.0  
  None 79 39.1 63 31.3  
Lymphatic Invasion      
  Yes 27 13.4 43 21.5 0.0315
  No 175 86.6 157 78.5  
  Missing 0   1   
Age group       
  <50 yrs 73 36.1 84 41.8 0.2447
  ≥50 yrs 129 63.9 117 58.2  
  1. aUnknown, not done or missing
  2. bIncludes mucinous, lobular and tubular subtypes
  3. cBy Chi-square test (without Missing category)
  4. dWithout ND group